Advertisement

Journal of Neurology

, Volume 264, Issue 7, pp 1370–1380 | Cite as

Optical coherence tomography for the diagnosis and monitoring of idiopathic intracranial hypertension

  • Philipp Albrecht
  • Christine Blasberg
  • Marius Ringelstein
  • Ann-Kristin Müller
  • David Finis
  • Rainer Guthoff
  • Ella-Maria Kadas
  • Wolf Lagreze
  • Orhan Aktas
  • Hans-Peter Hartung
  • Friedemann Paul
  • Alexander U. Brandt
  • Axel Methner
Original Communication

Abstract

The objectives of the study were to investigate the value of optical coherence tomography in detecting papilledema in patients with idiopathic intracranial hypertension (IIH), a disease which is difficult to monitor and which can lead to permanent visual deficits; to analyze retinal changes over time. In this non-interventional case–control study, spectral-domain optical coherence tomography (SD-OCT) was used to analyze the retinal and optic nerve head (ONH) morphology of 21 patients with IIH and 27 age- and sex-matched healthy controls over time. We analyzed the ONH volume using a custom-made algorithm and employed semi-automated segmentation of macular volume scans to assess the macular retinal nerve fiber layer (RNFL) and ganglion cell layer and inner plexiform layer complex as well as the total macular volume. In IIH patients, the ONH volume was increased and correlated with cerebrospinal fluid (CSF) pressure. The ONH volume decreased after the initiation of treatment with acetazolamide. The macular RNFL volume decreased by 5% in 3.5 months, and a stepwise multivariate regression analysis identified CSF pressure as the main influence on macular RNFL volume at diagnosis. The only factor predicting macular RNFL volume loss over time was ONH volume. SD-OCT can non-invasively monitor changes in retinal and ONH morphology in patients with IIH. Increased ONH volume leads to retinal atrophy in the form of macular RNFL volume loss, presumably due to mechanic jamming of the optic nerve at the disc and subsequent axonal loss.

Keywords

Idiopathic intracranial hypertension Optical coherence tomography 

Notes

Acknowledgements

The authors would like to thank Cheryl Ernest for proofreading.

Author contributions

PA conceived the study, performed data acquisition and analysis and drafted the manuscript. CB performed data acquisition and analysis, revised the manuscript for intellectual content and created the artwork. MR performed data acquisition and analysis and revised the manuscript for intellectual content. A-KM performed data acquisition and analysis and revised the manuscript. E-MK performed data analysis and revised the manuscript. DF performed data acquisition and revised the manuscript for intellectual content. RG revised the manuscript for intellectual content. OA revised the manuscript for intellectual content and helped with the interpretation of the data. H-PH revised the manuscript for intellectual content and helped with the interpretation of the data. FP revised the manuscript for intellectual content and helped with the interpretation of the data. AB performed data analysis, revised the manuscript for intellectual content and helped with the interpretation of the data. AM drafted and revised the manuscript for intellectual content and interpreted the data.

Compliance with ethical standards

Funding

The authors received no funding for the study.

Conflicts of interest

Philipp Albrecht received research grants from Novartis, Biogen Idec, Teva, Merz Pharmaceuticals and travel/accommodation/meeting expenses from Novartis, Teva, Biogen Idec, Merz Pharmaceuticals, Ipsen, Esai and GlaxoSmithKline. Christine Blasberg declares no conflicts of interest. Marius Ringelstein received speaker honoraria from Novartis and Bayer Vital GmbH and travel reimbursement from Bayer Schering and Biogen Idec. Ann-Kristin Müller received travel grants from Novartis. Ella-Maria Kadas declares nothing to disclose. David Finis received speaker honoraria and travel grants from Thea-Pharma, TearScience and Oculus. David Finis is now an employee of Bayer Pharma AG, Wuppertal, Germany. Rainer Guthoff received speaker honoraria and travel/accommodation/meeting expenses from Novartis and Bayer Schering. Orhan Aktas received grants from the German Research Foundation (DFG), Eugène Devic European Network (EU-FP7), German Ministry of Education and Research, Schaufler Foundation, honoraria for lectures from Almirall, Novartis, Bayer, Genzyme, Teva, Merck Serono, Biogen, Roche and Medimmune, and received travel/accommodation/meeting expenses from Novartis, Bayer Schering and Merck Serono. Hans-Peter Hartung received grants from the Walter and Ilse Rose Foundation, the Eugène Devic European Network (EU-FP7) and the German Ministry of Education and Research, received honoraria for consultancy from Bayer Health Care, Biogen Idec, Geneuro, Genzyme, Medimmune, Novartis, Opexa, Receptos, Teva, Sanofi Aventis, and Hoffman La Roche and holds patents. Friedemann Paul received research support, travel grants and personal compensation for activities with Bayer, Teva, Sanofi Genzyme, Merck Serono, Biogen and Novartis. He is supported by the German Research Foundation (DFG Exc 257), the Germany Ministry of Education and Research (BMBF Competence Network Multiple Sclerosis), the European Framework Program (EU-FP7, http://www.combims.eu) and the Guthy Jackson Charitable Foundation. Alexander U. Brandt has received consulting fees and speaker honoraria from Novartis, Biogen, Bayer, Teva, Motognosis and Heidelberg Engineering. He is named as co-inventor on a patent application encompassing the optic nerve head volume algorithm. Axel Methner received research and travel grants from Biogen Idec, Novartis and TEVA Pharma.

Ethical standards

The local ethics committee of Heinrich Heine University Düsseldorf approved this prospective observational study. Written informed consent was obtained from all participants in accordance with the Declaration of Helsinki.

Supplementary material

415_2017_8532_MOESM1_ESM.tif (190 kb)
Supplemental Figure: Peripapillary Ring Scans in IIH patients. (A/B) Box-and-whisker plots of the mean baseline values for the retinal nerve fiber layer thickness (RNFL) and the total retinal thickness (TRT), measured in peripapillary ring scans centered on the optic disc. The analysis revealed a significant reduction of peripapillary RNFL thickness and TRT in IIH patients compared with healthy controls. (C/D) Box-and-whisker plots of the baseline values and the first follow-up visit (visit 1) as well as p-values for their comparison (GEE analysis) are provided for the peripapillary RNFL and TRT. The investigation only includes those IIH patients who performed a follow-up measurement which was of sufficient quality for analysis: Peripapillary RNFL thickness as well as TRT were significantly reduced in IIH patients at follow-up compared to the baseline. (E/F) Box-and-whisker plots of the mean rates of change per month (Δμm/month) for the different retinal intervals and retinal parameters. Bars in the boxes mark the median, boxes the interquartile range and whiskers minimum and maximum. Numbers of eyes are indicated. P-values for differences for comparison between the IIH patients and healthy controls (A-B), between the baseline and visit 1 (C-D) and between the intervals (E–F) are indicated (bar, GEE analysis) as well as the P-values for differences to zero (E–F, bar, GEE analysis; below the boxes, one-sample t test of left eyes) (TIFF 190 kb)

References

  1. 1.
    Markey KA, Mollan SP, Jensen RH et al (2016) Understanding idiopathic intracranial hypertension: mechanisms, management, and future directions. Lancet Neurol 15:78–91. doi: 10.1016/S1474-4422(15)00298-7 CrossRefPubMedGoogle Scholar
  2. 2.
    Friedman DI, Liu GT, Digre KB (2013) Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. Neurology 81:1159–1165. doi: 10.1212/WNL.0b013e3182a55f17 CrossRefPubMedGoogle Scholar
  3. 3.
    Mollan SP, Ali F, Hassan-smith G et al (2016) Evolving evidence in adult idiopathic intracranial hypertension : pathophysiology and management. doi: 10.1136/jnnp-2015-311302 Google Scholar
  4. 4.
    Olesen J, Bousser G, Diener HC et al (2004) The international classification of headache disorders: 2nd edn. Cephalalgia 24 (Suppl 1):9–160CrossRefGoogle Scholar
  5. 5.
    Wall M, McDermott MP, Kieburtz KD et al (2014) Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial. JAMA 311:1641–1651. doi: 10.1001/jama.2014.3312 CrossRefPubMedGoogle Scholar
  6. 6.
    Peng K, Fuh J, Wang S (2012) Intracranial hypertension and its mimics. Nat Rev Neurol Gr 8:700–710. doi: 10.1038/nrneurol.2012.223 CrossRefGoogle Scholar
  7. 7.
    Radhakrishnan K, Ahlskog JE, Cross SA et al (1993) Idiopathic intracranial hypertension (pseudotumor cerebri). Descriptive epidemiology in Rochester, Minn, 1976 to 1990. Arch Neurol 50:78–80. http://www.ncbi.nlm.nih.gov/pubmed/8418804. Accessed 30 Apr 2016
  8. 8.
    Albrecht P, Blasberg C, Lukas S et al (2015) Retinal pathology in idiopathic moyamoya angiopathy detected by optical coherence tomography. Neurology 85:521–527. doi: 10.1212/WNL.0000000000001832 CrossRefPubMedGoogle Scholar
  9. 9.
    Kaufhold F, Kadas EM, Schmidt C et al (2012) Optic nerve head quantification in idiopathic intracranial hypertension by spectral domain OCT. PLoS One 7:e36965. doi: 10.1371/journal.pone.0036965 CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Hartmann CJ, Klistorner AI, Brandt AU et al (2014) Axonal damage in papilledema linked to idiopathic intracranial hypertension as revealed by multifocal visual evoked potentials. Clin Neurophysiol. doi: 10.1016/j.clinph.2014.12.014 Google Scholar
  11. 11.
    Ringelstein M, Albrecht P, Kleffner I et al (2015) Retinal pathology in Susac syndrome detected by spectral-domain optical coherence tomography. Neurology 85:610–618. doi: 10.1212/WNL.0000000000001852 CrossRefPubMedGoogle Scholar
  12. 12.
    Albrecht P, Müller A-K, Südmeyer M et al (2012) Optical coherence tomography in parkinsonian syndromes. PLoS One 7:e34891. doi: 10.1371/journal.pone.0034891 CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Albrecht P, Ringelstein M, Müller A-K et al (2012) Degeneration of retinal layers in multiple sclerosis subtypes quantified by optical coherence tomography. Mult Scler 18:1422–1429. doi: 10.1177/1352458512439237 CrossRefPubMedGoogle Scholar
  14. 14.
    Albrecht P, Müller A-K, Ringelstein M et al (2012) Retinal neurodegeneration in Wilson’s disease revealed by spectral domain optical coherence tomography. PLoS One 7:e49825. doi: 10.1371/journal.pone.0049825 CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Optical T, Tomography C, Committee S (2015) Papilledema outcomes from the optical coherence tomography substudy of the idiopathic intracranial hypertension treatment trial. Ophthalmology. doi: 10.1016/j.ophtha.2015.06.003 Google Scholar
  16. 16.
    Kadas EM, Kaufhold F, Schulz C et al (2012) 3D optic nerve segmentation in idiopathic intracranial hypertension. Bildverarbeitung für die Medizin 2012:261–267Google Scholar
  17. 17.
    Tewarie P, Balk L, Costello F et al (2012) The OSCAR-IB consensus criteria for retinal OCT quality assessment. PLoS One 7:e34823. doi: 10.1371/journal.pone.0034823 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Cruz-Herranz A, Balk LJ, Oberwahrenbrock T et al (2016) The APOSTEL recommendations for reporting quantitative optical coherence tomography studies. Neurology. doi: 10.1212/WNL.0000000000002774 PubMedCentralGoogle Scholar
  19. 19.
    Sinclair AJ, Burdon MA, Nightingale PG et al (2010) Low energy diet and intracranial pressure in women with idiopathic intracranial hypertension: prospective cohort study. BMJ 341:c2701. doi: 10.1136/bmj.c2701 CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Bäuerle J, Nedelmann M (2011) Sonographic assessment of the optic nerve sheath in idiopathic intracranial hypertension. J Neurol 258:2014–2019. doi: 10.1007/s00415-011-6059-0 CrossRefPubMedGoogle Scholar
  21. 21.
    Lochner P, Brio F, Zedde ML et al (2016) Feasibility and usefulness of ultrasonography in idiopathic intracranial hypertension or secondary intracranial hypertension. BMC Neurol. doi: 10.1186/s12883-016-0594-3 Google Scholar
  22. 22.
    Salgarello T, Tamburrelli C, Falsini B et al (1996) Optic nerve diameters and perimetric thresholds in idiopathic intracranial hypertension. Br J Ophthalmol 80:509–514CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Hainline C, Rucker JC, Balcer LJ (2016) Current concepts in pseudotumor cerebri. Curr Opin Neurol 29:84–93. doi: 10.1097/WCO.0000000000000273 CrossRefPubMedGoogle Scholar
  24. 24.
    Batra R, Sinclair A (2014) Idiopathic intracranial hypertension; Research progress and emerging themes. J Neurol 261:451–460. doi: 10.1007/s00415-013-7019-7 CrossRefPubMedGoogle Scholar
  25. 25.
    Raftopoulos R, Hickman SJ, Toosy A et al (2016) Phenytoin for neuroprotection in patients with acute optic neuritis : a randomised, placebo-controlled, phase 2 trial. Lancet Neurol 15:259–269. doi: 10.1016/S1474-4422(16)00004-1 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  • Philipp Albrecht
    • 1
  • Christine Blasberg
    • 1
    • 2
  • Marius Ringelstein
    • 1
  • Ann-Kristin Müller
    • 1
  • David Finis
    • 2
  • Rainer Guthoff
    • 2
  • Ella-Maria Kadas
    • 3
  • Wolf Lagreze
    • 4
  • Orhan Aktas
    • 1
  • Hans-Peter Hartung
    • 1
  • Friedemann Paul
    • 3
    • 5
  • Alexander U. Brandt
    • 3
  • Axel Methner
    • 6
  1. 1.Department of NeurologyHeinrich Heine University, Medical FacultyDüsseldorfGermany
  2. 2.Department of OphthalmologyHeinrich Heine University, Medical FacultyDüsseldorfGermany
  3. 3.NeuroCure Clinical Research Center and Clinical and Experimental Multiple Sclerosis Research Center, Department of NeurologyCharité-Universitätsmedizin BerlinBerlinGermany
  4. 4.Department of OphthalmologyUniversity Medical CenterFreiburgGermany
  5. 5.Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité Universitätsmedizin BerlinBerlinGermany
  6. 6.Focus Program Translational Neuroscience (FTN), Rhine Main Neuroscience Network (RMN(2)), Department of NeurologyJohannes Gutenberg University Medical CenterMainzGermany

Personalised recommendations